NASDAQ:KRYS

Krystal Biotech Stock Forecast, Price & News

$58.44

-1.41 (-2.36 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$57.98

▼

$61.03

50-Day Range

$57.00

▼

$71.77

52-Week Range

$39.39

▼

$87.29

Volume75,889 shs

Average Volume118,679 shs

Market Capitalization$1.30 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.13

30 days | 90 days | 365 days | Advanced Chart

Receive KRYS News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

About Krystal Biotech

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech (NASDAQ:KRYS) Shares Gap Up to $61.09
July 20, 2021 | americanbankingnews.com

Krystal Biotech (NASDAQ:KRYS) Stock Rating Upgraded by The Goldman Sachs Group
July 20, 2021 | americanbankingnews.com

Comparing Krystal Biotech (NASDAQ:KRYS) & Cabaletta Bio (NASDAQ:CABA)
July 20, 2021 | americanbankingnews.com

Krystal Biotech Breaks Below 200-Day Moving Average - Notable for KRYS
July 14, 2021 | nasdaq.com

-$0.74 EPS Expected for Krystal Biotech, Inc. (NASDAQ:KRYS) This Quarter
July 11, 2021 | americanbankingnews.com

Krystal Biotech picks Whiting-Turner for gene therapy center construction
July 7, 2021 | bizjournals.com

Krystal Biotech's (KRYS) "Buy" Rating Reiterated at Chardan Capital
July 7, 2021 | americanbankingnews.com

Krystal Biotech's KB105 Shows Detectable, Functionally Active TGM-1 Enzyme In Genetic Skin Condition
July 2, 2021 | finance.yahoo.com

Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
July 1, 2021 | finance.yahoo.com

Krystal Biotech is Now Oversold (KRYS)
May 13, 2021 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRYS
Previous Symbol
CUSIPN/A
CIK1711279
Webwww.krystalbio.com
Phone412-586-5830
Employees75
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$14.82 per share
Price / Book3.94

Profitability

EPS (Most Recent Fiscal Year)($1.71)
Net Income$-32,170,000.00
Net MarginsN/A
Return on Equity-12.78%
Return on Assets-12.33%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares22,200,000
Market Cap$1.30 billion
Next Earnings Date8/9/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.27 out of 5 stars

Medical Sector

130th out of 842 stocks

Biological Products, Except Diagnostic Industry

22nd out of 103 stocks

3.5 Analyst's Opinion

Consensus Rating
Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $101.00, Krystal Biotech has a forecasted upside of 72.8% from its current price of $58.44.
Amount of Analyst Coverage
Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

4.5 Community Rank

Outperform Votes
Krystal Biotech has received 250 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Krystal Biotech has received 123 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Krystal Biotech has received 67.02% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Krystal Biotech and other stocks. Vote “Outperform” if you believe KRYS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KRYS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Krystal Biotech does not currently pay a dividend.
Dividend Growth
Krystal Biotech does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Krystal Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.40% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.11% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Krystal Biotech are expected to decrease in the coming year, from ($2.88) to ($2.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Krystal Biotech is -27.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Krystal Biotech is -27.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Krystal Biotech has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech or view top-rated stocks.

What stocks does MarketBeat like better than Krystal Biotech?

Wall Street analysts have given Krystal Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Krystal Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Sunday, May, 9th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.12.
View Krystal Biotech's earnings history.

How has Krystal Biotech's stock price been impacted by COVID-19?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KRYS stock has increased by 17.1% and is now trading at $58.44.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KRYS?

6 brokers have issued twelve-month price targets for Krystal Biotech's shares. Their forecasts range from $90.00 to $115.00. On average, they expect Krystal Biotech's share price to reach $101.00 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price.
View analysts' price targets for Krystal Biotech or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

Mr. Krish S. Krishnan, Chairman, Pres & CEO (Age 56, Pay $752.37k)
Ms. Suma M. Krishnan, Founder, COO & Director (Age 56, Pay $532.27k)
Ms. Kathryn A. Romano, Chief Accounting Officer (Age 40, Pay $200.87k)
Ms. Gloria Lin, Accounting Mang.
Mr. John Karakkal, VP of North American Sales and Marketing
Ms. Katherine Tuminello, HR & Office Mang.
Mr. Josh Suskin, Director of HR & Operations
Ms. Pooja Agarwal, Sr. VP of Product Devel. (Age 42)
Ms. Whitney Glad Ijem, Sr. VP of Strategy & Bus. Devel.
Dr. Andreas C. Orth, Chief Commercial Officer

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Vir Biotechnology (VIR), Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Editas Medicine (EDIT), NanoString Technologies (NSTG) and Kymera Therapeutics (KYMR).
View all of KRYS's competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.09%). Company insiders that own Krystal Biotech stock include Daniel Janney, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends for Krystal Biotech.

Which major investors are buying Krystal Biotech stock?

KRYS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Krystal Biotech or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $58.44.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.30 billion. The company earns $-32,170,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at 412-586-5830 or via email at [email protected]

This page was last updated on 7/31/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here